Antiretroviral Trials

Currently Enrolling

Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Contact: Rosie Clarke
(416)340-4800 ext. 6723


Probiotic VSL#3 for Inflammation and Translocation in HIV II (PROOV IT II)

Sponsor: University Health Network

Contact: Bryan Boyachuk or Warmond Chan
(416)340-4800 ext. 4239 or 6954


Not Enrolling, but Ongoing

A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (MK-1439A-024)

Sponsor: Merck Sharp & Dohme Corp.

Contact: Warmond Chan
(416)340-4800 ext. 6954


A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (AI438-047)

Sponsor: Bristol-Myers Squibb

Contact: Warmond Chan
(416)340-4800 ext. 6954


A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/ Tenofovir or Abacavir/ Lamivudine to GS-9883/ Emtricitabine/ Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (GS-US-380-1878)

Sponsor: Gilead Sciences

Contact: Warmond Chan
(416)340-4800 ext. 6954


A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects (TMC114IFD3013)

Sponsor: Janssen R&D Ireland

Contact: Adriana D’Aquila
(416)340-4800 ext. 8170


A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects (GS-US-366-1160)

Sponsor: Gilead Sciences

Contact: Bryan Boyachuk
(416)340-4239


A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) (GS-US-366-1216)

Sponsor: Gilead Sciences

Contact: Bryan Boyachuk
(416)340-4239


A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults Who Are Virologically Suppressed (SWORD-1)

Sponsor: ViiV Healthcare

Contact: Rosie Clarke
(416)340-4800 ext. 6723

A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With Truvada or Epzicom/Kivexa, in Treatment-Naïve HIV-1 Infected Subjects (Protocol: MK-1439-018)

Sponsor: Merck Sharp & Dohme

Contact: Adri D’Aquila
(416)340-4800 ext. 8170

Completed Studies with Results

A Phase 2b Randomized, Active-Controlled, Staged, Open-label Trial to Investigate Safety and Efficacy of BMS-955176 in Combination With Dolutegravir and Atazanavir (With or Without Ritonavir) in Treatment-Experienced HIV-1 Infected Adults (AI468-048)


A Case Control Study of Novel Bone Imaging Techniques and Plasma Markers in HIV-infected Persons With or Without Fragility (CTNPT-001)


Prospective Observational Epidemiologic Study of Maraviroc’s Safety (POEM). (A4001067)


A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults. (GS-US-183-0145)


Study for Assessing the Effectiveness of the New Integrase Inhibitor GSK1349572 in HIV-infected Persons With Prior Antiretroviral Treatment and Resistance to Raltegravir (ING112961)


A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults (ING111762)


Vicriviroc in Combination Treatment with Optimized ART Regimen in Experienced Subjects: Open-Label Phase (P03672 VICTOR-E1)


A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects (A4001027)


Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation (CARE 001)


A Phase II Study Testing The Activity and Safety of AGS-004 as an Immunotherapeutic in Successfully ART-treated Subjects Infected with HIV-1 in Combination with ART Followed by ART Interruption (CTN 239)


A Large, Simple Trial Comparing Two Strategies for Management of Antiretroviral Therapy (CTN 190)


A Tri-national (Canada, UK, USA) Randomized, Controlled Trial to Determine the Optimal Management of Patients with HIV Infection for Whom First and Second-line Highly Active Antiretroviral Therapy Has Failed. CTN 167, OPTIMA

A Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/Lamivudine from Current Antiretroviral Regimen Compared with Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed. (STRIIVING, GSK Protocol 201147)


Randomized, Open-label Study Evaluating Efficacy and Safety of Maraviroc as a Switch for Either NRTI or PI/r in HIV-1 Infected Individuals With Stable, Well-Controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of cART (MARCH)


A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects (MK-1439-018)


A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults (GS-US-292-1249)

A Phase 3, Randomized, Open-Label, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF. (GS-US-311-1089)


A Phase 3, Open-Label Study to Evaluate Switching From a TDF-containing Combination Regimens to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-suppressed, HIV-1 Positive Subjects (GS-US-292-0109)